FIG 1.

EF24 attenuated malignant phenotypes of triple-negative breast cancer (TNBC) cells and decreased HCG11 expression in vivo. BALBC/c nude mice were divided into MDA-MB-231+control, MDA-MB-231+EF24, MDA-MB-468+control, and MDA-MB-468+EF24 groups (n = 6 for each group). On day 0, 1 × 10⁶ MDA-MB-231/MDA-MB-468 were subcutaneously injected into mice. On days 14 to 28, EF24 (3 mg/kg/d) was intraperitoneally injected into mice in MDA-MB-231+EF24 and MDA-MB-468+EF24 groups. The xenograft tumor volumes were calculated at days 0, 7, 14, 21, and 28 in (A) MDA-MB-231+control and MDA-MB-231+EF24 groups, and (B) MDA-MB-468+control and MDA-MB-468+EF24 groups. On day 28, all mice were euthanized and the xenograft tumors were collected. (C) Representative images of immunohistochemical staining for Ki-67 (scale bars = 5 μm). (D) Representative images of TUNEL assay (scale bars = 50 μm). (E) Representative images of immunohistochemical staining for E-cadherin (E-cad) and vimentin (scale bars = 5 μm). Shapiro-Wilk test was used to check whether the data follow a normal distribution and F-test was used to verify if the variances were significantly different. F-test P < 0.05: a heteroskedasticity t test. F-test P ≥ 0.05: a homoscedastic t test. ***, P < 0.001 versus MDA-MB-231+control; *, P < 0.05; **, P < 0.01 versus MDA-MB-468+control.